Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor, Adult
- Metastatic Solid Tumor
- Refractory Cancer
- CRC, Colorectal Cancer
- RCC, Clear Cell Adenocarcinoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Endometrial Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sairopa B.V.
- Last updated on ClinicalTrials.gov
- December 17, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Henry Ford Cancer Institute · Detroit, MI
Missouri · 1
- Washington University Medical Campus · St Louis, MO
Ohio · 1
- Gabrail Cancer & Research Center · Canton, OH
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.